Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile

Knapper, Steven, Chevassut, Timothy, Duarte, Rafael, Bergua, Juan Miguel, Salamero, Olga, Johansen, Malin, Jacobsen, Tove Flem, Hals, Petter-Arnt, Rasch, Wenche, Gianella-Borradorif, Athos and Smith, Matthew (2014) Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile. Leukemia Research, 38 (3). pp. 346-351. ISSN 0145-2126

[img] PDF - Published Version
Restricted to SRO admin only

Download (732kB)

Abstract

Elacytarabine is the elaidic acid ester derivative of cytarabine, designed to enter cells independently of nucleoside transporters. Effects of elacytarabine on QT interval, serum lipid profile and clinical activity were investigated in 43 relapsed/refractory AML patients. Mean maximum increase in corrected QT interval of 24( ± 29)ms occurred 48 h after elacytarabine infusion without associated arrhythmias or clinical symptoms. A non-clinically significant, elacytarabine exposure-dependent increase in cholesterol was caused by a cholesterol rich lipoprotein depleted of apolipoprotein B formed by infused phospholipids complexing cholesterol. Elacytarabine is clinically active in relapsed/refractory AML: overall response rate (CR + CRi) was 44% (16/36 with 7 non-evaluable patients) and adverse events were manageable.

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Brighton and Sussex Medical School
Subjects: R Medicine > R Medicine (General)
Depositing User: Timothy Chevassut
Date Deposited: 14 May 2014 09:10
Last Modified: 08 Mar 2017 05:35
URI: http://sro.sussex.ac.uk/id/eprint/48628

View download statistics for this item

📧 Request an update